From Cheers to Jeers; Stakeholders Scrutinize Price of Amylyx ALS treatment
Yesterday, there was widespread celebration across stakeholders following the FDA approval of Amylyx’s treatment for ALS, Relyvrio. Now, cheers are turning to criticism, after the price of the drug was announced by the company this morning on their investor call.